Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
NCT05827770Phase 2Unknown
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in melanoma. Status: unknown.
02
Drugs
toripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05827770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827770.